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ABSTRACT
Aims To compare the change in illicit opioid users’ risk of fatal drug-related poisoning (DRP) associated with opioid
agonist pharmacotherapy (OAP) and psychological support, and investigate the modifying effect of patient characteristics,
criminal justice system (CJS) referral and treatment completion. Design National data linkage cohort study of the
English National Drug Treatment Monitoring System and the Ofﬁce for National Statistics national mortality database.
Data were analysed using survival methods. Setting All services in England that provide publicly funded, structured
treatment for illicit opioid users. Participants Adults treated for opioid dependence during April 2005 to March 2009:
151983 individuals; 69% male; median age 32.6 with 442950 person-years of observation. Measurements The
outcome was fatal DRPoccurring during periods in or out of treatment, with adjustment for age, gender, substances used,
injecting status and CJS referral. Findings There were 1499 DRP deaths [3.4 per 1000 person-years, 95% conﬁdence
interval (CI) =3.2–3.6]. DRP risk increased while patients were not enrolled in any treatment [adjusted hazard ratio
(aHR)=1.73, 95% CI=1.55–1.92]. Risk when enrolled only in a psychological intervention was double that during
OAP (aHR=2.07, 95% CI=1.75–2.46). The increased risk when out of treatment was greater for men (aHR=1.88,
95% CI=1.67–2.12), illicit drug injectors (aHR=2.27, 95% CI=1.97–2.62) and those reporting problematic alcohol
use (aHR=2.37, 95% CI=1.90–2.98). Conclusions Patients who received only psychological support for opioid
dependence in England appear to be at greater risk of fatal opioid poisoning than those who received opioid agonist
pharmacotherapy.
Keywords Drug-related poisoning, opiate dependence, opioid agonist pharmacotherapy, overdose, psychosocial
treatment, residential treatment.
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INTRODUCTION
Non-medical use of opioid drugs is associated with a signif-
icant global burden of disease [1]. In the United Kingdom,
1% of the illicit opioid-using population dies each year
[2,3]. More than half of these deaths are due to respiratory
failure following accidental overdose [3–5].
Opioid agonist pharmacotherapy (OAP) is a community
treatment for opioid dependence which aims to reduce her-
oin and other non-medical opioid use and associated harm.
Using oral methadone or buprenorphine, well-delivered
OAP manages the patient’s physiological dependence,
attenuates drug use cravings and facilitates access to
health-care and recovery supports. Meta-analyses of
randomized controlled trials show that OAP is effective at
retaining patients in treatment and reducing heroin use
[6–8]. The World Health Organization (WHO) and the
National Institute for Health and Care Excellence (NICE)
recommend OAP as the front-line maintenance treatment
for opioid dependence [9,10]. Oral methadone and
buprenorphine are also used for medically supervised
withdrawal in community and hospital settings.
Most developed health-care systems also provide
psychological support interventions to treat opioid depen-
dence. Guided by individual need, preference and any
previous clinical response, these interventions are offered
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either concurrently or sequentially with OAP, or they are
offered as a stand-alone treatment with no substitute
medication.
Widely delivered in the United Kingdom, community-
setting psychological support comprises a broad set of
structured change methods which aim to reduce the
opioid-dependent person’s cognitive behavioural symp-
toms, intra/interpersonal difﬁculties and social problems
and build motivation for recovery. The patient is assigned
a clinical key worker to help develop, implement and
review their care plan [11]. Psychological support inter-
ventions are also provided by residential rehabilitation
services; these programmes are guided by a characteristic
philosophical approach and vary in duration and intensity.
NICE recommends that people with drug-related prob-
lems are provided with information about self-help groups
and that those outside structured treatment are offered
brief motivational interventions [12]. NICE endorses con-
tingency management (which uses practical reinforcers
to motivate adherence to treatment and behaviour
change) as an adjunctive therapy during OAP but judges
that there is insufﬁcient evidence to recommend routine
use of cognitive behavioural therapy or psychodynamic
therapy. Standalone psychological support for opioid
dependence is also not recommended—with the exception
of behavioural couples therapy for those who have an
appropriate non-drug-misusing partner.
Observational studies of addiction treatment systems
have reported that the risk of fatal drug-related poisoning
(DRP) is at least halved when patients are enrolled in treat-
ment for opioid dependence [5,13], with this risk increas-
ing immediately following the start of treatment and after
it ends [14,15]. However, to date, estimation of the change
in DRP risk associated with psychological support inter-
ventions has been hampered by limited statistical power
in small-scale controlled trials and meta-analyses [16].
Large-scale research is therefore needed to inform
policy and service providers about the DRP risk associated
with psychological support interventions and identify
modiﬁers of treatment impact. Isolating the individual
effect of a particular treatment is challenging, because
people may receive several different treatments in an
episode of care and over time [17]. An episode of treatment
can comprise a single intervention, or several interventions
delivered in combination or sequence (e.g. OAP then
psychological intervention; psychological support followed
by residential rehabilitation; and so on).
Previous studies have identiﬁed male gender, older
age, illicit drug injecting and concurrent use of central
nervous system depressants (e.g. alcohol and benzodiaz-
epines) as independent risk factors for DRP [3,5,14,18].
We included these as potential modiﬁers of treatment
effects along with two additional measures: referral from
the criminal justice system (CJS); and whether the
clinical service reported that the patient had completed
their treatment successfully.
Approximately a quarter of treatment admissions in
England are CJS referred [19], and this subpopulation is
less likely to abstain from heroin during treatment [20].
Most CJS-referred treatment involves standard provision
of care, with a very small minority of cases mandated to
treatment by the court. The goal of completing treatment
abstinent from opioid use (illicit or otherwise) has been a
recent priority for a recovery-orientated policy in the
United Kingdom [21,22].
To investigate the DRP risk for community psychologi-
cal support and residential interventions and compare it
with the risk associated with OAP, we developed a national
Drug Data Warehouse [23] project to link treatment and
mortality data in England. We asked three questions in this
study:
1 What is the DRP risk associated with time patients
spend in treatment and time spent out of treatment?
2 What is the DRP risk associated with psychological
support in comparison to OAP?
3 Is the association between treatment andDRP riskmod-
erated by: referral and patient characteristics; the ﬁrst
month after admission and discharge; and by successful
completion of treatment?
METHODS
Design
This was a national data linkage study of the English Na-
tional Drug Treatment Monitoring System (NDTMS) and
the Ofﬁce for National Statistics (ONS) mortality database.
NDTMS is a national system that monitors the delivery of
all public treatment for psychoactive substance-related
problems by National Health Service and third-sector pro-
viders [24], which together account for almost all such
provision in England. The ONSmortality database includes
all registered deaths in England and Wales. Data extracted
from these databases were linked for a 4-year observation
period (1April 2005 to 31March 2009).
Patient and treatment information
NDTMS records four types of treatment: community OAP,
community psychological support, in-patient withdrawal
management and drug-free residential rehabilitation.
Enrolment in in-patient and residential treatment each
provided a small number of person-years (1224 and
2601, respectively). We noted that this reduced statistical
power for an intervention level analysis. As both interven-
tions are abstinence orientated, we judged it appropriate to
create a combined grouping (labelled ‘residential’).
During the observation period, 191310 adults (aged
18–64 years) were treated for opioid dependence (for 1 or
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more days). Some patients received one treatment episode,
while others received several episodes during this time. The
date on which each patient started and ended each treat-
ment enabled us to classify time spent in the following
mutually exclusive groups: residential (with or without
OAP or psychological support); OAP (with or without
psychological support); and psychological support alone
(Fig. 1 shows a schematic illustration of the construction
of these treatment groups).
For each opioid treatment episode, the following
clinic admission information from NDTMS was used for
the analysis: gender; age; referral source; self-reported
illicit drug injecting status (past month); and an optional
self-report of up to three additional problematic psycho-
active substances which were relevant at admission
[25]. The status of the patient at discharge was catego-
rized according to the assessment of the clinical service
as either ‘successfully completed’ or ‘not completed’.
Only illicit drug injecting status included a ‘not
answered’ code for missing data.
DRP mortality
The ONS provided data on all deaths occurring during the
observation period which were registered by 30September
2011. This allowed for delays in the registration process
pending inquest verdicts, as recommended for research
[26].
Deaths due to DRP were identiﬁed from the following
WHO International Classiﬁcation of Disease (ICD-10)
codes: ‘mental and behavioural disorders due to psychoac-
tive substance use, excluding alcohol and tobacco’
(F11–16, F18–19); ‘accidental poisoning by drugs, medi-
caments and biological substances’ (X40–X44); ‘inten-
tional self-poisoning drugs, medicaments and biological
substances’ (X60–X64); ‘assault by drugs, medicaments
and biological substances’ (X85); and ‘poisoning by drugs,
medicaments and biological substances, undetermined
intent’ (Y10–Y14) [27].
Data linkage procedure
Treatment and mortality data were linked using a mini-
mal identiﬁer in each database (initials, date of birth,
gender) and government region of usual residence.
During preparatory work, we noted that when linking
NDTMS data with person-unique CJS identiﬁers, up to
22% of minimal identiﬁers in the treatment population
were shared by one or more individuals. This is an over-
estimation of the true rate at which patients shared the
same identifying characteristics because CJS identiﬁers
are entered manually into the database and are subject
to error. Conservatively, all such records were excluded
from the analysis to reduce false positive matching. This
created a cohort of 151 982 individuals for the present
study. All patient identiﬁers were irreversibly encrypted
to ensure that features of the original data could not be
discerned.
Following advice on the study procedure from the NHS
Central Ofﬁce for Research Ethics Committees and the
ofﬁce of the University of Manchester Research Ethics
Committee, approval for access to NDTMS and mortality
records was secured from the English National Treatment
Agency for Substance Misuse and the ONS Microdata
Release Panel, respectively.
Statistical analysis
Unadjusted and adjusted proportional hazard ratios (HR
and aHR) for the DRP risk were calculated by Cox regres-
sion (Stata release 13) with the calendar–time origin for
survival set to 1April 2005.
In-treatment status was deﬁned according to the dates
of admission/discharge for each treatment episode, identi-
ﬁed by time-dependent variables. Time spent out of treat-
ment started from the day after the end of a treatment
episode to the day prior to the start of a new episode (or
to end of follow-up if there were no further interventions
recorded). Individuals in the cohort entered the DRP
risk-set on 1April 2005 if they were already enrolled in
treatment, or they entered the risk-set from the start of
their ﬁrst treatment episode during the observation period.
Cohort members ceased to be at risk at 31March 2009, or
from the date of their death from any cause.
Typically, patients in the UK treatment system are
expected to attend their clinical service fortnightly or more
often. We noted that the discharge date could indicate
erroneously that a DRPoccurred out-of-treatment because
the clinical service recorded the patient’s last face-to-face
clinical contact as their discharge date (as per NDTMS
guidance [25]). We observed 130 deaths associated with
OAP and 18 associated with psychological support within
2weeks of discharge where the discharge reason was
‘died’. These were assigned as in-treatment deaths by
extending the date of discharge.
We adjusted the analysis for the following covariates
judged inﬂuential for DRP risk [2,3] or potential
confounders of DRP risk and treatment [20]: gender;
time-updated age (categorized as 18–35, 35–44, 45–64
Figure 1 Schematic diagram representing the categorization of treat-
ment modalities
300 Matthias Pierce et al.
© 2015 The Authors. Addiction published by JohnWiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 111, 298–308
years); patient-reported injecting status; patient-reported
problematic use of alcohol, benzodiazepines, crack cocaine
(the smokeable base form), cocaine powder and amphet-
amines (the latter two substances combined as ‘other stim-
ulants’ because of a low level of reporting); and referred
from CJS (analysis focus).
The following time-dependent covariates were
constructed:
1 the risk-set for illicit drug injecting and additional
problematic substances was deﬁned from the date of
ﬁrst report (as this occurred). Persons remained in that
risk-set until the end of the observation period;
2 the risk-set for CJS referral was deﬁned from the date of
treatment admission and this was updated (as neces-
sary) for a subsequent episode; and
3 discharge status (completed or not completed) was
deﬁned for the periods following discharge, until the
beginning of the next treatment-episode or the end of
the observation period.
We ﬁtted the following pre-speciﬁed interactions to
investigate effect modiﬁcation for the relationship
between treatment and changed DRP risk, with statisti-
cal signiﬁcance set at P<0.01: gender; age (over 35 or
not); DRP behavioural risks (injecting, problematic
alcohol and benzodiazepine use); and CJS referral.
Effect-modiﬁcation was assessed by individually ﬁtting
each of these six interactions and testing their statistical
signiﬁcance by likelihood ratio tests. To test joint effects
of each reported interaction, all six interactions were
included in a single, adjusted model.
The following time-dependent indicators were used to
investigate DRP risk following admission and discharge:
the 28 days following admission; the intervening time
enrolled in each treatment; and the 28 days following
discharge (providing no further treatment was received).
If an episode comprised a sequence of more than one type
of treatment (deﬁned hierarchically), the ﬁrst 28 days out
of treatment was assigned to discharge from the last treat-
ment. The referent category was the intervening period
enrolled in OAP. Using a categorical time-dependent
variable, the out-of-treatment DRP risk for those classiﬁed
as having completed treatment successfully was compared
with the risk for those who did not successfully complete
treatment. Graphical plots of Schoenfeld residuals were
used to check for the proportional hazard assumption in
all regression models.
There were two sensitivity checks. First, given the like-
lihood of imprecision in the reporting of treatment episode
dates, the analyses were repeated with discharge dates
extended by 14 days for patients who did not complete
treatment. Secondly, to allow for length-biased accrual,
analyses were performed separately for treatment episodes
which started before and those which started on or after
1April 2005.
RESULTS
Between 1April 2005 and 31March 2009, the 151983
individuals in the cohort contributed 4423.4 person-years
(PY) of observation and 236660 treatment episodes to the
analysis (Table 1).
During the study there were 1499 DRP-related deaths:
a DRP mortality rate of 3.4 per 1000 PY [95% conﬁdence
interval (CI) =3.2–3.6]. The following covariates were as-
sociated with an increase in DRP risk: increasing age, drug
injecting, problematic alcohol use, problematic benzodiaze-
pine use and male gender (Table 2). Covariate associations
were stable across all regression models (see Appendix A in
Supporting information).
Risk in and out of treatment
During treatment the DRP mortality rate was 2.9 (95%
CI=2.7–3.1) per 1000 PY and was 4.5 (95%
CI=4.1–4.9) per 1000 PYduring periods out of treatment
(Table 2). After adjustment, DRP risk was associated
strongly with periods spent out of any treatment.
Table 3 shows the risk modiﬁcation for treatment
enrolment status by referral and patient characteristics.
The overall association of treatment with reduced DRP risk
was substantially greater for males (P=0.002), illicit drug
injectors (P<0.001), and patients who reported problem-
atic alcohol use (P=0.002). There was insufﬁcient evi-
dence of a treatment effect for patients referred from the
CJS in contrast to non-CJS referred patients (P<0.001).
Risk and treatment type
After covariate adjustment, the DRP risk associated with
community psychological support was twice that associ-
ated with OAP (Table 4). There was no evident difference
in risk between periods spent in residential treatment and
periods in OAP.
DRP risk early in treatment and after discharge
The ﬁrst 28 days of OAP were associated with a lower
DRP risk than that associated with the period enrolled
in this treatment thereafter (Table 4). There was no evi-
dence of changed DRP risk between the ﬁrst month and
the remainder of psychological support. There were no
deaths in the ﬁrst 28 days after admission to residential
treatment.
The DRP risk increased during the month immedi-
ately following discharge from OAP but there was
weaker evidence of an increase during the month follow-
ing discharge from psychological support. Patients
discharged from residential treatment had approxi-
mately twice the risk associated with discharge from
OAP. There was evidence that the increased DRP risk
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persisted for the period beyond the ﬁrst month following
discharge from any treatment.
There was insufﬁcient evidence for a difference in
post-treatment DRP risk between patients judged to have
completed treatment successfully and those who did not
(P=0.11).
Sensitivity analyses and assumption checks
We extended the recorded date of discharge for non-
completed treatment by 14 days and also repeated the
analyses separately for episodes which started before or
after 1 April 2005 to assess duration-biased accrual. These
analyses did not inﬂuence the inferences made (see
Appendices B and C, Supporting information). Following
each model ﬁtted, graphical analysis of the Schonfeld
residuals revealed no substantial departures from the
vassumption of proportional hazards.
DISCUSSION
We observed an elevated DRP risk during periods out of
any treatment for opioid dependence. During treatment
there was a greater reduction in this risk for men, for illicit
drug injectors and those who reported problematic alcohol
use and, consistent with meta-analysis [6–8], OAP was
associated with a strong reduction in DRP risk. The DRP
risk increased during the month following discharge from
OAP or residential treatment and elevated risk persisted
beyond the month following discharge.
The DRP risk associated with psychological support
was twice that for OAP (aHR=2.07, 95% CI=1.75–2.46)
and was comparable to the risk when not in treatment.
This is consistent with an earlier observation that ‘drug-
free’ treatment is associated with a higher all-cause mor-
tality risk [28]. This is unlikely to reﬂect elevated risk on
transition from OAP to psychological support. In fact, this
Table 1 Cohort description, follow-up time, deaths and covariates (n=151983 individuals).
Category Full sample
Demographics 69%
Total number of individuals 151 983
Number (%) of individuals who were
Male 105 172 (69)
Female 46811 (31)
Median age (IQR) at cohort entry, years 32.6 (27.2, 38.9)
Observation period
Total person-years of observation 442 950
Number (%) of person-years of observation spent
Out of any treatment 135 864 (31)
In any treatment 307 086 (69)
Number (%) of person-years in treatment according to type of intervention received
Pharmacotherapy 272 280 (89)
Psychological support 30977 (10)
Residential 3825 (1)
Median person-years (IQR) of observation per individual 3.4 (2.0, 4.0)
Treatments
Total number of treatment episodes 236 660
Number (%) of treatment episodes that included each intervention typea
Pharmacotherapy 190 339 (80)
Psychological support 69033 (29)
Residential 17193 (7)
Number (%) of individuals who received (during observation period)
One treatment episode 99416 (65)
Two treatment episodes 32285 (21)
Three treatment episodes 12711 (8)
Four treatment episodes 4813 (3)
Five or more treatment episodes 2758 (2)
Deaths
Total number recorded during observation period 3503
Number (%) of deaths that were due to
Drug-related poisoning 1499 (43)
Other causes 2004 (57)
aPercentages here round to > 100% because an episode could include more than one type of intervention. IQR = interquartile range.
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clinical pathway was extremely rare in the cohort and this
transition occurred in only 1% of treatment episodes (see
Appendix D, Supporting information).
There was no evidence that completing treatment
successfully was associated with a reduction in DRP
risk, nor was DRP risk reduced during treatment
among people referred from the CJS. We conducted a
post-hoc analysis to determine whether this might be
due to the inclusion of those referred following release
from prison, because this confers a substantially ele-
vated risk of mortality [29]. However, the association
between treatment and risk remained weak, even for
non-prison CJS referrals (see Appendix E, Supporting
information).
In contrast to previous studies, we found no elevation
in risk at OAP treatment onset. This may reﬂect more effec-
tive recent adherence to guidelines for initiation of opioid
prescribing at the predominantly specialist treatment
settings studied here compared to the primary care setting
of an earlier English study [15].
Small-scale, uncontrolled studies have observed reduc-
tions in drug use among CJS referrals [30,31]. However,
the present results concur with ﬁndings from a large-scale
cohort indicating that CJS referral is associated with a
reduced likelihood of the patient achieving abstinence or
reducing drug use [20]. It has been suggested that the
crime reduction and administrative demands in the CJS
may limit time for clinical interventions to treat depen-
dence [32].
Our study has several strengths. This is the largest
cohort study on DRP risk to be published to date, compris-
ing England-wide data from all publicly funded opioid
dependence treatment services in the NHS and third-sector
providers. It afforded sufﬁcient statistical power to explore
Table 2 Unadjusted and covariate adjusted Cox regression of risk of fatal drug-related poisoning (DRP) during time in and out of treatment
(n=151 983 individuals).
Variable
Person-years,
1000 No. of DRPs
DRP rate, per 1000
person-years HR aHR P-value
Status
In treatment 307 890 2.9 (2.7, 3.1) 1 1 < 0.001
Not in treatment 136 609 4.5 (4.1, 4.9) 1.57 (1.42, 1.75) 1.73 (1.55, 1.92)
Covariates
Gender
Male 303 1162 3.8 (3.6, 4.1) 1 1 < 0.001
Female 140 337 2.4 (2.2, 2.7) 0.63 (0.56, 0.71) 0.70 (0.62, 0.79)
Age group (years)
18–34 236 608 2.6 (2.4, 2.8) 0.63 (0.57, 0.71) 0.64 (0.57, 0.72) < 0.001
35–44 150 608 4.1 (3.7, 4.4) 1 1
45–64 57 283 5.0 (4.4, 5.6) 1.23 (1.07, 1.41) 1.31 (1.13, 1.51)
Drug injectinga
Yes 163 788 4.8 (4.5, 5.2) 2.15 (1.93, 2.41) 2.12 (1.89, 2.37) < 0.001
No 235 526 2.2 (2.1, 2.4) 1 1
Not declared 45 185 4.1 (3.6, 4.7) 1.82 (1.54, 2.16) 1.77 (1.50, 2.10)
Alcohola
Yes 55 313 5.6 (5.1, 6.3) 1.84 (1.64, 2.10) 1.72 (1.52, 1.95) < 0.001
No 387 1186 3.1 (2.9, 3.2) 1 1
Benzodiazepinesa
Yes 60 288 4.8 (4.3, 5.4) 1.53 (1.34, 1.74) 1.44 (1.26, 1.64) < 0.001
No 383 1211 3.2 (3.0, 3.3) 1 1
Crack cocainea
Yes 162 559 3.4 (3.2, 3.7) 1.03 (0.93, 1.15) 0.98 (0.88, 1.09) 0.71
No 280 940 3.4 (3.1, 3.6) 1 1
Other stimulantsa
Yes 58 227 3.9 (3.4, 4.5) 1.19 (1.03, 1.37) 1.10 (0.96, 1.27) 0.17
No 385 1272 3.3 (3.1, 3.5) 1 1
Following CJS referralb
Yes 82 279 3.4 (3.0, 3.8) 1.01 (0.89, 1.16) 0.97 (0.85, 1.11) 0.65
No 361 1220 3.4 (3.2, 3.6) 1 1
Numbers in parentheses are 95% conﬁdence intervals (CIs); DRP, fatal (opioid) drug-related poisoning; HR = hazard ratio; aHR = adjusted HR (for all other
variables); HR/aHR = value of 1 denotes baseline category. aPatient reported: additional, concurrent problem to opioid dependence at treatment assessment
(time dependent covariate; not declared are missing data). bFrom start to subsequent treatment-episode. CJS = criminal justice system.
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interactions and comparison of DRP risk for OAP and
psychological support interventions. The ﬁndingswere also
robust to sensitivity analysis around the date of treatment
discharge and between prevalent and incident treatment
episodes (Appendices B and C, respectively; Supporting
information). The data linkage design delivered minimal
loss to follow-up, although we note that this design is not
able to account for cohort loss due to people who leave
the country.
We also acknowledge several limitations. First, the
start date for OAP is more clearly identiﬁed than its
end date, because treatment cessation may only become
apparent once a patient has failed to present for a repeat
prescription. Our approach to recording end-of-treatment
differed from those in some previous studies (e.g. utiliz-
ing prescription end-date) [15]. Prescription data may
have provided better information on when medication
was provided. However, prescriptions may continue to
be issued beyond when patients cease to collect them.
In Australia, Degenhardt and colleagues deﬁned a period
after the end of recorded discharge when the patient was
assumed still to be in treatment [14], whereas our
approach assumed this only if we had a prior expectation
(i.e. when discharge was recorded as being due to death;
n=148).
Secondly, the observational design limits the capacity to
make causal inferences. Uncontrolled confounding may
account for some of the differences in DRP risk reported,
and we lacked case-mix information on opioid dependence
severity and co-existing health and social problems to
strengthen the analysis. Also, because the variables describing
behavioural risk factors are interval-censored (i.e. informa-
tion is only available at the start of treatment), controlling
for these is likely to account for only part of the confound-
ing. However, adjustment for the evidence-supported
covariates that were available indicated confounding away
from the null (unadjusted HR=2.00; aHR=2.07).
Thirdly, NDTMS data did not specify the speciﬁc
methods of psychological support received by patients;
thus, variability in the receipt of such treatment could not
be explored. Similarly, it was not possible to distinguish
the relative effects ofmethadone and buprenorphinewithin
OAP, and this may have led to a loss of information. Both of
these are accessible in the publicly funded, community-
based UK treatment setting. We note recent work indicat-
ing a lower risk associated with buprenorphine during early
treatment [33], although previous UK research has not dif-
ferentiated the DRP risk by agonist medication either early
in treatment or post-discharge [15]. Our group is now
investigating this issue using another treatment database.
Table 3 Cox regression of DRP risk during time in and out of treatment modiﬁed by referral and patient characteristics (n=151 983
individuals).
Effect modiﬁer
Treatment
status
Person-years,
1000 No. of DRPs
DRP rate, per
1000 PY HR aHR P-valuea
Gender
Male In 207 659 3.2 (2.9, 3.4) 1 1 0.002
Out 96 503 5.2 (4.8, 5.7) 1.68 (1.49, 1.88) 1.88 (1.67, 2.12)
Female In 100 231 2.3 (2.0, 2.6) 1 1
Out 40 106 2.7 (2.2, 3.2) 1.17 (0.93, 1.47) 1.26 (1.00, 1.59)
Injecting
Injector In 121 457 3.8 (3.4, 4.1) 1 1 < 0.001
Out 42 331 7.9 (7.1, 8.8) 2.13 (1.85, 2.46) 2.27 (1.97, 2.62)
Not injector/undeclared In 186 433 2.3 (2.1, 2.6) 1 1
Out 94 278 3.0 (2.6, 3.3) 1.30 (1.11, 1.51) 1.36 (1.17, 1.58)
Alcohol
Yes In 40 172 4.3 (3.7, 5.0) 1 1 0.002
Out 16 141 9.1 (7.7, 10.7) 2.16 (1.73, 2.70) 2.37 (1.90, 2.98)
No In 267 718 2.7 (2.5, 2.9) 1 1
Out 120 468 3.9 (3.6, 4.3) 1.48 (1.31, 1.66) 1.59 (1.41, 1.79)
CJS referral
Yes In 48 164 3.4 (2.9, 4.0) 1 1 < 0.001
Out 34 115 3.4 (2.8, 4.1) 1.01 (0.80, 1.28) 1.15 (0.90, 1.46)
No In 259 726 2.8 (2.6, 3.0) 1 1
Out 102 494 4.8 (4.4, 5.3) 1.76 (1.56, 1.97) 1.90 (1.69, 2.14)
Numbers in parentheses are 95% conﬁdence intervals (CIs); HR = hazard ratio; DRP = fatal (opioid) drug-related poisoning; aHR= adjusted HR (for all variables
present in Table 2—see Appendix A for covariate estimates); HR/aHR= value of 1 denotes baseline category. aLikelihood ratio tests of comparison with adjusted
model in Table 2 (i.e. test for effect modiﬁcation). Two further variables tested for effect modiﬁcation, but with P> 0.01 (adjusted models): benzodiazepine use
P = 0.03; age P = 0.87. All interactions were ﬁtted individually in adjusted model. As a sensitivity check, all interactions were included in a single, adjusted
model to test their independence: the results were very similar to those reported here. DRP = drug-related poisoning; CJS = criminal justice system.
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The elevated risks observed on discharge from OAP and
residential treatments are consistent with previous studies
[14,15]. This is likely to be mediated by reduced opioid tol-
erance [34], due to dose tapering and cessation of prescrib-
ing at discharge. The nature of residential treatment may
vary across countries; as provided in the United Kingdom
it is an intensive, non-mandatory intervention received
by patients who appear more amenable to treatment
[35]. Further, appropriately powered research is needed
to contrast the DRP associated with discharge from
in-patient and residential rehabilitation services.
The treatment classiﬁcation of successful completion
(i.e. a conclusion of the patient’s care plan and discharge
mutually agreed) has face validity as an indicator of clin-
ical effectiveness. Recent treatment policy in the United
Kingdom has emphasized monitoring of this criterion as
an important indicator of effectiveness [21,22]. However,
this is a proxy indicator of clinical response and service
providers may or may not use objective biological testing
to document abstinence.We could ﬁnd little evidence of a
difference in DRP risk between those judged to have
completed or not completed treatment. It is possible that
the former patients faced greater risk of DRP on relapse,
while non-completers had higher levels of opioid toler-
ance from which they derived some protection [36].
In conclusion, our ﬁndings show that: (1) DRP risk is
lower during treatment and substantially higher out of
treatment; (2) psychological support is associated with
twice the risk observed for OAP; and (3) that successfully
completing treatment is not associated with a reduction
in risk. Because psychological support was the secondmost
common pattern observed in the present study, we recom-
mend that there should be a clear focus upon identifying
and reducing overdose risk in patients who receive stand-
alone psychological support for opioid dependence. Opioid
overdose should be an explicit discussion topic with
patients who present for psychological support.
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